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Abstract
Introduction: The article focuses on the studies which point to particular difficulties in achieving compliance in pe-
diatrics. A dangerous trend to escalate the number and doses of antibiotics in anti- Helicobacter pylori (HP) schemes, 
the dosage frequency and course duration of eradication therapy considerably complicates a patient’s compliance to the 
treatment and contributes to a further growth of HP antibiotic resistance. In the treatment of children, the control of the 
outpatient therapy largely depends on the patient’s parents.
Materials and methods: At the first stage of the study, 103 children with chronic gastroduodenal pathology associated 
with HP were examined. Diagnosis of the disease was based on the study of complaints, the anamnesis data, and the 
results of the endoscopic examination. All the patients underwent a course of anti-HP therapy in the outpatient setting. A 
degree of parental compliance to their child’s therapy was determined in by a questionnaire, which had been developed 
by us, the families of the children suffering from chronic gastroduodenal pathology. At the second stage, 80 children 
suffering from peptic ulcer associated with HP were examined. HP was eradicated in the outpatients of both groups, 
using an anti-HP regimen: omeprazole, clarithromycin, and amoxicillin administered for 14 days. The influence of the 
measures to improve parental compliance carried out in tandem “doctor – pharmacist” in the families with children 
suffering from chronic gastroduodenal pathology was studied.
Results and discussion: A decrease in parental compliance was observed in more than 2/3 of the families with children 
suffering from chronic gastroduodenal pathology, associated with HP infection. A higher level of parental compliance 
was established in the families of children after the ”compliance training”. In the patients of this group, eradication of 
HP was achieved in 87.5% cases by using a traditional scheme: omeprazole, clarithromycin, and amoxicillin adminis-
tered for 14 days.
Conclusion: It can be concluded that the level of parental compliance to an anti-HP therapy for their children is insuf-
ficient. In turn, conducting a “compliance training” in the tandem of ”doctor – pharmacist” before starting the therapy 
is an important factor in increasing the level of parental compliance, which is reflected in increasing the effectiveness 
of the treatment. Strict adherence to the regimen and duration of administration of the prescribed drugs in children 
with ulcer allows achieving a high level of HP eradication – 95.2 %, even when using the traditional anti-HP regimen.
The eradication was achieved in 56.5 % of the children with partial parental compliance, and only in 6.7 % of the chil-
dren with non-compliant parents.
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unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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Introduction
The chronic diseases of the stomach and the duodenum are 
the most common chronic inflammatory diseases of the 
gastrointestinal tract (GIT). To date, Helicobacter pylori 
(HP) infection is considered as the main cause of chronic 
gastroduodenal pathology (CGDP) and the formation of 
its most severe forms in patients of different age groups 
(Fasciana et al. 2019, Leja et al. 2019). Most aspects of 
HP eradication in pediatric practice remain unresolved. 
Anti-HP therapy is the main standard of treatment for pa-
tients with inflammatory and destructive processes of the 
stomach and the duodenum (Lee et al. 2013). However, 
in recent years, a number of problems associated with the 
development of HP resistance to the antibiotics, which are 
traditionally used to eradicate this microorganism, have 
arisen (Gressot et al. 2019, Megraud et al. 2013, Savoldi 
et al. 2018, Thung et al. 2016, Vianna et al. 2016).
According to the recommendations of Maastricht IV-V 
and the Kyoto Global Consensus on HP-associated gas-
tritis and the National Guidelines to diagnose and treat 
acid-related and HP-associated diseases (VI Moscow 
Agreement), the use of high doses of proton pump in-
hibitors, an increase in the antibiotics course duration to 
14 days, four-component sequential antibiotic regimens, 
and the use of fluoroquinolones are important ways to 
improve the effectiveness of anti-HP therapy in patients 
with CGDP (Malfertheiner et al. 2012, Malfertheiner et 
al. 2017, Sugano et al. 2015). However, these recommen-
dations in pediatric practice remain difficult to implement 
due to the high frequency of side effects and little expe-
rience in using certain medicines in childhood. In addi-
tion, fluoroquinolones, widely used for HP eradication in 
adults, are contraindicated for use in pediatric practice.
A dangerous trend to escalate the number and doses 
of antibiotics used in anti-HP schemes, their dosage fre-
quency and course duration of eradication therapy con-
siderably complicates a patient’s compliance to the treat-
ment, reduces the quality of life, increases the frequency 
of side effects, which leads to reduced compliance and 
contributes to a further growth of HP resistance to antibi-
otics (Andreev and Kucherjavyj 2013, Cimmerman and 
Vologzhanina 2015, Kalach et al. 2015, Maev et al. 2013, 
O`Connor et al. 2009).
Today, control over the regular implementation of the 
appointments of the attending physician by the patient is 
the key to effective treatment of any disease, especially 
this is relevant in relation to chronic pathology.
Compliance is the conformity of the patient’s behavior 
to the physician’s recommendations, including medica-
tions, diet and/or lifestyle changes. Often, compliance is 
viewed as the conscious cooperation of the physician and 
the patient, as well as the latter’s family members, which 
is a prerequisite for any treatment, ensuring the effective-
ness of the therapy (Danilov 2014). The patient’s compli-
ance with the therapy, his/her active participation in the 
treatment process,strict adherence to prescribed treatment 
regimens and diet therapy are of great importance for the 
treatment of chronic diseases and for a successful therapy 
(Naletov et al. 2018).
The problem of compliance among patients suffering 
from chronic pathology of the GIT is currently particu-
larly relevant, as these diseases have chronic recurrent 
course, resulting in a significant decrease in the quality 
of the patient’s life, to long-term limitations in diet and 
changing toilet habits, which has an impact on the psy-
chological state of the patient, exacerbating the course of 
the disease, disappointing the patients in the therapy and 
discouraging the physicians (Beljakova 2014).
The results of the studies point to certain difficulties in 
achieving compliance in pediatrics. In the treatment of chil-
dren, the control over the therapy in an outpatient setting 
largely depends on the patient’s parents (Naletov et al. 2017).
The active inclusion of pharmacists (whose compe-
tence is to provide advice to the population and specialists 
on the use of medicines) in the activities aimed at im-
proving the compliance of sick children and their parents, 
with overloaded physicians of the primary stage of med-
ical care for children, may contribute to the optimization 
of the therapy.
Materials and methods
At the first stage of the study, 103 children (young teens 
(12–14 years of age) and teenagers (15–17 years of age) 
with CGDP associated with HP (peptic ulcer, chronic 
gastroduodenitis) were examined at Donetsk City Child-
ren’s Clinical Hospital No. 1 and Donetsk Medical Center 
”Gastro-line” to determine a degree of parental complian-
ce to their children’s therapy.
The diagnosis of CGDP was based on the study of 
complaints, anamnesis data, and results of the endoscopic 
examination.
All the patients underwent an outpatient course of an-
ti-HP therapy. After the course, during a consultation with 
patients and their parents, an anonymous survey was con-
ducted to determine the level of parental compliance by 
using a questionnaire, which had been developed for this 
study (Table 1).
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The questionnaire is highly valid (Cronbach test was over 
0.8). Sensitivity  =  92.8%, specificity  =  82.4%, false-nega-
tive values  =  7.2%, false-positive values  =  17.6%.
At the second stage, 80 children (young teens (12–14 
years of age) and teenagers (15–17 years of age)) suffer-
ing from peptic ulcer associated with HP were examined.
Diagnosis of HP infection was carried out by two meth-
ods (invasive and non-invasive). A Helpil test system was 
used for quick urease test with biopsy material (AMA Co 
Ltd., Russia). A Helik test system with indicator tubes 
was used for urease breath test (AMA Co Ltd., Russia). 
HP infection was determined if both methods provided 
positive results.
Before treatment, an anonymous questionnaire, which 
had been specially designed for this study, was conducted 
with the parents of the patients included in the study, de-
termining the level of parental compliance.
Further,, all the patients were divided into two groups: 
group 1 and group 2. There were 40 children in each 
group. HP was eradicated in the patients of both groups in 
outpatient setting, using an anti-HP regimen: omeprazole, 
clarithromycin, and amoxicillin adminiatered for 14 days. 
This scheme is regulated by the Federal Clinical Guide-
lines for the Provision of Medical Care to Children with 
Gastric Ulcer and Duodenal Ulcer Disease (2016).
The patients of group 1 were prescribed a treatment 
during a consultation with a pediatric gastroenterologist 
at Donetsk City Children’s Clinical Hospital No. 1.
The patients of group 2 were consulted by a pediat-
ric gastroenterologist and pharmacist at Donetsk Medi-
cal Center ”Gastro-line” before starting the therapy, with 
their parents present. During the 20-minute consultation, 
in order to increase the level of compliance, a ‘compli-
ance training” was conducted for the patient’s parents 
and the child. During the ”training”, the doctor explained 
the causes and mechanisms of the disease, the need and 
expediency of strict adherence to a two-week course of 
anti-HP therapy with 2 antibiotics. In turn, the pharmacist 
during the ”training” dwelled on the issues of the dos-
age regimen, potential side effects of the therapy, and the 
interaction of the components of the proposed medicine 
scheme, as well as the approximate possible cost of treat-
ment; a medication diary was made to be filled in, speci-
fying the daily order of medications on the scheme. Later, 
every three days, the pharmacist would call up with the 
patient’s parents and answer the questions they had about 
the order and regimen of taking the drugs.
The effectiveness of the eradication with the use of 
noninvasive respiratory urease test, the dynamics of 
clinical symptoms, and a level of parental compliance 
were determined in the children during the control visit 1 
month after the treatment.
There was no statistically significant difference in age 
between the comparison groups (p > 0.05, Mann-Whitney 
U-test), and no statistically significant difference in sex 
distribution (p > 0.05, Mann-Whitney U-test).
The study met all the ethical requirements for scientific 
work, and was conducted with the permission of the eth-
ics committee of the M. Gorky Donetsk National Medical 
University. Before the examination, all the parents were 
informed of the nature of the clinical study, the prescrip-
tion of medicine and possible side effects. The studies 
were carried out after obtaining informed consents to par-
ticipate in the studies from the parents / legal representa-
tives of the child.
The STATISTICA 7 package was used for statistical 
analysis of the data. Comparisons of groups of quantita-
tive data were carried out using one-factor analysis and 
multiple comparison methods: the Scheffe method (in the 
case of the normal distribution law); the Dann’s multiple 
comparison tests (in the case of the difference between 
the distribution law and the normal distribution law). The 
comparison of the mean qualitative data was performed, 
using a paired fraction comparison (Fisher’s angular 
transformation with Yates’ correction). In the case of mul-
tiple comparison of proportion, the Bonferroni correction 
was used. The tables show the average value of the indi-
cator of the frequency of the feasture manifestation (%) 
and its 95% confidence interval (95% CI).
Results and discussion
At the first stage, in order to study parental compliance in 
families of children suffering from CGDP, an anonymous 
survey was conducted among the parents of the children 
receiving different schemes of HP eradication. When ana-
lyzing parental compliance in the families of children suf-
fering from HP-associated CGDP, it was found that the 
majority of parents were not compliant with their child-
ren’s treatment. When using the developed questionnaire 
to assess a level of parental compliance, it was found that 
in the examined patients only in 31 (30.1 ± 4.5 %) fami-
lies, the parents were compliant with the anti-HP therapy 
Table 1. Questionnaire to determine the level of parental compliance.
№ Question ”Yes” “No”
1 Have you ever forgotten to give your child the medicine? 0 1
2 Do you sometimes disregard your child’s medication intake time? 0 1
3 Do you skip taking the medicine if your child feels well? 0 1
4 If the child does not feel well after taking the medicine, do you skip the next dose? 0 1
5 May you refuse the next dose of the drug due to the child’s negative reaction to taking the medicine? 0 1
6 Can you independently replace the prescribed drug in your child’s treatment with a “more effective 
and safer” drug, in your opinion, without consulting the attending physician?
0 1
Note: 6 points – compliance, 4, 5 points – partial compliance, 3 or less points – non-compliance.
Barinova AS et al.: Parental compliance on the effectiveness of  treatment in children72
used in the treatment of their children. In these families, 
strict adherence to the regimen of drugs prescribed by a 
specialist to eradicate HP infection was observed. A de-
crease in parental compliance was observed in more than 
2/3 of the surveyed families. Thus, in 34 (33.0 ± 4.6 %) 
cases, there was partial compliance of parents with the 
treatment received by their child, and in 38 (36.9 ± 4.8 %) 
– parents were non-compliant.
It was found that in 48 (46.6 ± 4.9 %) families of the 
children suffering from CGDP, the parents would forget 
about the drug taking schedule of the children. In some 
families, the parents tended to have their children skip 
drug taking in case of the child’s negative reaction – 44 
(42.7 ± 4.9 %) families, or if the patient got unwell after 
the previous drug-taking – 42 (40.8 ± 4.8 %) families. In 
32 (31.1 ± 4.6 %) cases, the parents admitted their neg-
ligence as to the drug taking schedule.There was also an 
earlier completion of the anti-HP treatment after the gen-
eral condition of the patient had improved – 15 (14.6 ± 
3.5 %) cases. In 20 (19.4 ± 3.9 %) families, the parents 
could, without prior consultation with the attending phy-
sician, replace one or more components of the drug regi-
men with a medicine which they viewed as ”more effec-
tive”, or reduce the dose of the antibiotic.
The results obtained at the first stage of the study in-
dicate that in most cases the parents do not strictly com-
ply with the prescriptions of the attending physician in 
relation to the eradication therapy. This actually prevents 
the patient from receiving a full course of therapy, which 
can subsequently affect the effectiveness of HP eradica-
tion. So it is necessary to find ways to increase parental 
compliance in relation to their children’s therapy. In the 
conditions of heavily loaded doctors of polyclinics and 
hospitals, the work of the pharmacist may be an effective 
way to increase parental compliance.
At the second stage of the study, the effectiveness of 
the measures developed for this study – in tandem “doc-
tor-pharmacist” to increase the level of parental compli-
ance in order to improve the effectiveness of the treatment 
of children suffering from peptic ulcer disease (eradica-
tion of HP, relief of the main clinical symptoms).
It was found that the initial level of parental compli-
ance in the comparison groups had no statistically signifi-
cant differences (р > 0.05) (Table 2).
After a two-week course of anti-HP therapy, the impact 
of the “compliance training” on the increased adherence 
of the parents of the children suffering from HP-associat-
ed СGDP was analyzed. The level of significance of dif-
ferences in the distribution of parental compliance in the 
families of the examined patients was statistically signifi-
cant – p < 0.001 (Table 3).
In group 2, the patients whose parents were compliant 
with their children’s course of eradication therapy prevailed 
– 30 (75.0 ± 6.8 %). In group 1, the level of parental com-
pliance did not have a statistically significant (p > 0.05) 
difference from the baseline. This positive dynamics of 
compliance in patients of group 2 seems to result from the 
”compliance training” conducted with the parents of the pa-
tients of this group before the start of the anti-HP therapy.
When studying the effectiveness of HP infection erad-
ication, statistically significant differences in this indi-
cator were established between the comparison groups 
(p < 0.001). In the patients of group 1, HP eradication was 
achieved in 47.5 % of cases. In the patients of group 2, 
eradication of HP was achieved in 87.5 % cases (p < 0.001).
There were significant differences between the effects 
of parental compliance on the effectiveness of HP infec-
tion eradication among the patients of both groups (p < 
0.001). The most effective eradication of HP infection was 
observed among the patients whose parents were commit-
ted to the treatment (42 children in both groups) – 95.2 % 
(95% CI 86.5 % - 99.6 %), which exceeds the minimum 
permissible level of eradication of 80–90 % when apply-
ing anti-HP regimens recommended by The Internation-
al and National Guidelines. At the same time, this level 
of eradication was statistically significantly higher (p < 
0.001) relative to that in the patients with partial parental 
compliance (23 children in both groups) – 56.5 % (95% 
CI 35.1 % – 6.7 %), and the children with non-compli-
ant parents (23 children in both groups) – 6.7 % (95% CI 
0.0 % – 26.3 %), p = 0.002.
The results indicate that strict parental control over the 
prescriptions of the attending physician in relation to their 
child’s therapy allows for a high level of HP eradication 
without the use of aggressive eradication schemes.
Further, the dynamics of clinical syndromes of CGDP 
(pain and dyspeptic syndromes) was studied in the com-
parison groups.
Table 2. Assessment of the initial level of parental competence in the groups of patients.
Level of parental compliance Group 1 (n = 40) аbs. (% ± m%) Group 2 (n = 40) аbs. (% ± m%) p-Fisher level
non-compliance 14 (35.0 ± 7.5 %) 13 (32.5 ± 7.4 %) > 0.05
partial compliance 14 (35.0 ± 7.5 %) 14 (35.0 ± 7.5 %) > 0.05
compliance 12 (30.0 ± 7.2 %) 13 (32.5 ± 7.4 %) > 0.05
Table 3. Assessment of parental competence level in the groups of patients during the control physician visit.
Level of parental compliance Group 1 (n = 40) аbs. (% ± m%) Group 2 (n = 40) аbs. (% ± m%) p-Fisher level
non-compliance 13 (32.5 ± 7.4 %) 2 (5.0 ± 3.4 %) < 0.05
partial compliance 15 (37.5 ± 7.7 %) 8 (20.0 ± 6.3 %) > 0.05
compliance 12 (30.0 ± 7.2 %) 30 (75.0 ± 6.8 %) < 0.001
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Among the patients of group 1, against the background 
of the anti-HP therapy course, 37.5% (95% CI 22.9% – 
53.4%) of patients complained of the abdominal pain. In 
group 2, these complaints were detected during a control 
physician visit in 17.5% (95% CI 7.2 % – 31.1%) children.
When studying the dynamics of dyspeptic syndrome 
against the background of the treatment, it was found that 
dyspeptic syndrome persisted in 35.0% (95% CI 20.8% – 
50.8%) of the patients of group 1 at the control physician 
visit. These complaints were detected during a control visit 
in 10.0% (95% CI 2.6% – 21.5%) of the patients of group 
2. The difference in indicators is at the level of p = 0.05.
The obtained results indicate that parents’ strict adher-
ence to the prescribed therapy regimen for their children 
makes it possible, against the background of effective 
eradication of HP, to achieve relief of the main clinical 
syndromes of the disease in a shorter time.
Conclusions
Thus, it was found that the level of parental complian-
ce to anti-HP therapy for their children is insufficient. In 
most cases, parents do not fully comply with the prescri-
bed treatment regimen, which is the reason for the incom-
plete course of eradication therapy recommended by the 
attending physician. In turn, conducting a “compliance 
training” in the tandem of ”doctor – pharmacist” before 
starting the therapy is an important factor in increasing 
the level of parental compliance in patients with CGDP, 
which is reflected in increasing the effectiveness of the 
treatment. Strict adherence to the regimen and duration 
of administration of the prescribed drugs in children with 
ulcer disease allows achieving a high level of HP eradi-
cation even when using the traditional anti-HP regimen.
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